NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase Ib clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase II clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438, which are in preclinical investigational studies for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: ngmbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2024 | Outperform → Mkt Perform | Raymond James | |
| 2/28/2024 | Outperform → Market Perform | TD Cowen | |
| 2/27/2024 | Buy → Neutral | Citigroup | |
| 5/3/2023 | $6.00 | Buy | Citigroup |
| 10/18/2022 | $29.00 → $4.00 | Buy → Neutral | Goldman |
| 10/18/2022 | $42.00 → $4.00 | Strong Buy → Outperform | Raymond James |
| 10/17/2022 | Buy → Hold | Jefferies | |
| 10/17/2022 | Overweight → Neutral | Piper Sandler | |
| 7/20/2022 | $25.00 | Buy | Jefferies |
| 11/5/2021 | $39.00 → $42.00 | Strong Buy | Raymond James |
15-12G - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
EFFECT - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
25-NSE - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
S-8 POS - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
S-8 POS - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
S-8 POS - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
S-8 POS - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
S-8 POS - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
POS AM - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
8-K - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus shamNGM621 showed favorable safety and tolerability, with no evidence of increased CNV conversion and no treatment-related SAEsAdditional analyses to be presented in early November at The Retina Society Annual Scientific MeetingNGM Bio to host conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced topline efficacy
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration. To access the live webcast and slides, please visit the "Investors & Media" section of NGM Bio's website at https://ir.ngmbio.com/. The webcast will be archived for 30 days. About NGM Bio NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives ha
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with 3 mg of aldafermin, an engineered FGF19 analog product candidate, compared to patients treated with placeboInitiated the first two Phase 2b expansion cohorts in the Phase 1/2 trial evaluating NGM707, an ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab)Announced the appointment of Dan Kaplan, Ph.D. to Chief Scientific OfficerExtended expected cash runway into the second quarter of 2025 following a restructuring o
INDIANAPOLIS, Feb. 8, 2022 /PRNewswire/ -- Marathon Health announces the addition of four members to its Board of Directors, as the company continues to accelerate plans to achieve its mission of fixing the U.S. health system by scaling its advanced primary care model. Ms. Obi Felton, Ms. Siobhan Nolan Mangini, Dr. Glenn Steele and Mr. Bill Whitely bring a strong and diverse set of track records and experience, spanning leadership in clinical quality, patient experience, technology, and rapid growth. Marathon's appointment of these four Directors comes at an exciting inflecti
Completed enrollment in 320-patient Phase 2 CATALINA study of NGM621, an anti-complement C3 antibody, for the treatment of geographic atrophy; topline data expected in second half of 2022Initiated a Phase 1/2 clinical trial of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumorsAmended collaboration with Merck to focus primarily on advancing novel medicines for retinal and cardiovascular and metabolic diseases; NGM gained worldwide rights to its disclosed oncology portfolio as well as additional assets falling outside of the amended collaboration's narrower scope$390.6 million in cash, cash equivalents and marketable securities as of June 30, 2021 SOUTH SAN
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. ("Parent"), an affiliate of The Column Group, LP ("TCG"), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. ("Merger Sub"), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain other stockholders at a price per share of $1.55 in cash (the "Offer Price"). The tender offer and related withdrawal rights expired at one minute a
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA. Poster Presentation Details: Title: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose esca
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravidarum (HG) by the end of 2024-- --Ongoing discussions with regulators on the design of a potential registrational trial of aldafermin, an engineered FGF19 analog, for the treatment of primary sclerosing chola
NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transactionBased on a thorough exploration and review of strategic and financial alternatives, a Special Committee of independent and disinterested directors unanimously recommends the transaction SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that it has entere
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET. A live webcast of the presentation will be available under the Investors and Media sections of NGM Bio's website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM Bio's site for 30 days following the eve
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer, will participate in the B. Riley Securities 4th Annual Oncology Conference and will provide a business update focusing on NGM Bio's wholly-owned oncology portfolio on Thursday, January 18th, at 2:30 pm ET. A replay of the presentation will be available under the Investors and Media section of NGM Bio's website at https://ir.ngmbio.com/events-presentations
Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer (CRC), in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody, in combination with KEYTRUDA® (pembrolizumab) Aldafermin, an engineered FGF19 analog, has been granted Orphan Drug Designation by the FDA for the treatment of primary sclerosing cholangitis (PSC), a rare liver disease Initiating design of a potential registrational trial of aldafermin in PSC and in discussion with the FDA on utilizing proposed surrogate endpoints with the goal of obtaining accelerated approvalLarge body of clinical data, including from NGM Bio's prior Phase 2
--As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment-- --ELF, an FDA-approved non-invasive blood test, can be used to predict liver-related events in patients with nonalcoholic steatohepatitis (NASH) and compensated cirrhosis-- --Dose-dependent improvements reported across histologic and multiple non-invasive secondary endpoints in ALPINE 4-- --In the trial, aldafermin treatment up to one year was generally well tolerated with no treatment-related serious adverse events-- SOUTH SAN FRANCISCO, Calif., Nov. 13, 20
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference and will present an overview of the company and provide a business update. Management will also be available for investor meetings at the upcoming Jefferies London Healthcare Conference. Jefferies London Healthcare Conference 2023November 14 – 16, 2023 6th Annual Evercore ISI HealthCONx ConferenceWednesd
--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438-- --Selected for an oral plenary presentation of data from Phase 2b ALPINE 4 trial of aldafermin in compensated cirrhosis (F4) due to NASH at upcoming AASLD The Liver Meeting®-- --Reported $166.0 million in cash, cash equivalents and marketable securities as of September 30, 2023, with expected cash runway into mid-2025-- SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a clinical-stage biotechnology company focused on discover
SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13G/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13G/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13G/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13G/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13G - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13G - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13G - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
Raymond James downgraded NGM Biopharmaceuticals from Outperform to Mkt Perform
TD Cowen downgraded NGM Biopharmaceuticals from Outperform to Market Perform
Citigroup downgraded NGM Biopharmaceuticals from Buy to Neutral
Citigroup initiated coverage of NGM Biopharmaceuticals with a rating of Buy and set a new price target of $6.00
Goldman downgraded NGM Biopharmaceuticals from Buy to Neutral and set a new price target of $4.00 from $29.00 previously
Raymond James downgraded NGM Biopharmaceuticals from Strong Buy to Outperform and set a new price target of $4.00 from $42.00 previously
Jefferies downgraded NGM Biopharmaceuticals from Buy to Hold
Piper Sandler downgraded NGM Biopharmaceuticals from Overweight to Neutral
Jefferies initiated coverage of NGM Biopharmaceuticals with a rating of Buy and set a new price target of $25.00
Raymond James reiterated coverage of NGM Biopharmaceuticals with a rating of Strong Buy and set a new price target of $42.00 from $39.00 previously
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
Raymond James analyst Steven Seedhouse downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Outperform to Market Perform.
NGM Biopharmaceuticals (NASDAQ:NGM) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 26.67 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $165.00 thousand which missed the analyst consensus estimate of $560.00 thousand by 70.54 percent. This is a 99.09 percent decrease over sales of $18.18 million the same period last year.
TD Cowen analyst Ritu Baral downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Outperform to Market Perform and lowers the price target from $4 to $1.55.
Shares of Freshpet, Inc. (NASDAQ:FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. Freshpet posted quarterly earnings of 31 cents per share, beating market estimates of 5 cents per share. The company’s quarterly sales came in at $215.42 million versus expectations of $204.36 million. Freshpet shares gained 15.5% to $106.29 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Akili, Inc. (NASDAQ:AKLI) shares jumped 126% to $0.5009 after the company reported positive results from Shionogi's Phase 3 clinical trial of localized version of Akili's EndeavorRx® for Pediatric ADHD patients in Japan. Z
On Monday, Venture capital firm The Column Group agreed to acquire NGM Biopharmaceuticals Inc (NASDAQ:NGM) for $1.55/share in cash. The Column Group is NGM Bio’s longest and largest stockholder, holding approximately 26% of NGM Bio’s outstanding shares. NGM Bio stock is trading lower with a session volume of 1.9 million, compared to the average volume of 1.02 million, as per the data from Benzinga Pro. The price per share corresponds to a total equity value of $135 million on a fully diluted basis and represents an 80% premium over the last trading day closing price (December 29, 2023) prior to NGM Bio’s Form 8-K confirming receipt from the TCG Stockholders of a non-binding express
Gainers Akili (NASDAQ:AKLI) shares rose 121.1% to $0.49 during Monday's regular session. The market value of their outstanding shares is at $38.3 million. ZyVersa Therapeutics (NASDAQ:ZVSA) stock rose 69.78% to $1.36. The company's market cap stands at $6.2 million. Ocean Biomedical (NASDAQ:OCEA) stock increased by 66.24% to $2.61. The company's market cap stands at $88.9 million. Krystal Biotech (NASDAQ:KRYS) stock moved upwards by 39.37% to $155.16. The company's market cap stands at $4.3 billion. The company's, Q4 earnings came out today. Milestone Pharmaceuticals (NASDAQ:MIST) shares increased by 38.23% to $2.35. The company's market cap stands at $78.6 million. Butterfly Network (
NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transactionBased on a thorough exploration and review of strategic and financial alternatives, a Special Committee of independent and disinterested directors unanimously recommends the transactionSAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that it has entered in